Spots Global Cancer Trial Database for chemotherapy naive
Every month we try and update this database with for chemotherapy naive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer | NCT00521404 | Pancreatic Canc... | CS-1008 (humani... gemcitabine | 18 Years - | Daiichi Sankyo | |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | NCT01445535 | T-Cell Peripher... Gamma Delta Hep... Subcutaneous Pa... NK T-Cell Lymph... | Rituximab Etoposide Siplizumab Prednisone Vincristine Cyclophosphamid... Doxorubicin | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | NCT00201838 | Pancreatic Neop... Adenocarcinoma | Gemcitabine Etanercept | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer | NCT00637247 | Pancreatic Neop... | imexon in combi... imexon placebo ... | 18 Years - | AmpliMed Corporation | |
| Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | NCT01313559 | Castrate Resist... Chemotherapy Na... Prostate Cancer | Pasireotide Everolimus Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma | NCT00409383 | Melanoma | Genasense® (obl... Abraxane® (pacl... Temodar® (temoz... | 18 Years - | Genta Incorporated | |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | NCT01323062 | Non Small Cell ... | Bavituximab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | NCT01445535 | T-Cell Peripher... Gamma Delta Hep... Subcutaneous Pa... NK T-Cell Lymph... | Rituximab Etoposide Siplizumab Prednisone Vincristine Cyclophosphamid... Doxorubicin | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | NCT00201838 | Pancreatic Neop... Adenocarcinoma | Gemcitabine Etanercept | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | NCT01323062 | Non Small Cell ... | Bavituximab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00103428 | Prostate Cancer | CG7870 | 18 Years - | Cell Genesys | |
| Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | NCT00201838 | Pancreatic Neop... Adenocarcinoma | Gemcitabine Etanercept | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer | NCT00521404 | Pancreatic Canc... | CS-1008 (humani... gemcitabine | 18 Years - | Daiichi Sankyo |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
